Herpes simplex keratitis

Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting

Retrieved on: 
Monday, April 22, 2024
Corneal opacity, AAV2, Nanopore, Rabbit, Immortalised cell line, Genomics, LTR, CRISPR, Genetic engineering, Abraxis BioScience, Infection, Gene, RNA, Recurrence, HeLa, Paratriathlon, Cell, HSK, AAV, Vero cell, Research, Pterygopalatine ganglion, FACS, PCR, Disease, DNA, Therapy, Viral load, HIV-1, Society, CDS, Gag, ICP0, Genome, Herpes simplex keratitis, LAT, Orientation, Annual general meeting, Edema, Valaciclovir, SAN, Vaccine

Herpes Simplex Keratitis (HSK), caused by the infection of herpes simplex virus type 1 (HSV-1) in the cornea, is a major cause of blindness worldwide.

Key Points: 
  • Herpes Simplex Keratitis (HSK), caused by the infection of herpes simplex virus type 1 (HSV-1) in the cornea, is a major cause of blindness worldwide.
  • Although current anti-HSV-1 therapies interfere with viral DNA replication, they do not eliminate HSV-1 reservoirs or prevent recurrence.
  • CRISPR/Cas-mediated gene editing can potentially address the underlying causes of the disease by directly eliminating the latent HSV-1 reservoirs.
  • The 440 guide RNA pairs formed with these 42 PlmCasX guide RNAs were tested in tissue culture for DNA excision efficiency.

Rational Vaccines' RVX1001 Vaccine Candidate Protects Against HSV Ocular Infection in vivo

Retrieved on: 
Tuesday, December 28, 2021
People, Antibody, Fissure, Company, World, Louisiana State University, Blister, Immune system, School, Fever, Department, VC2, WHO, Infection, HK, Herpes simplex keratitis, LSU, Vaccination, Myalgia, Vaccine, Virology, UC Davis School of Veterinary Medicine, Patient, Severe cognitive impairment, McQuillan, LSU School of Music, HSV-1, Alzheimer's disease, HSV-2, HSV, Mouse, Research, Prevalence, Virus, Veterinary medicine, Diagnosis, Cornea, Frontiers, Keratitis, Neutrophil, Chills, Genital herpes, Multimedia, Erythema, Dementia, Disease, Social stigma, Biotechnology, MRCVS, World Health Organization, BVM, Doctor of Philosophy, Simplex, Ulcer, Immunology

Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.

Key Points: 
  • Dr. Kousoulas stated, "These data provide in vivo proof of concept for the prophylactic treatment of herpetic keratitis with our HSV-1 vaccine.
  • Results showed that RVX1001 administered prophylactically protected mice against lethal ocular HSV-1 challenge and the development of herpetic keratitis.
  • Herpetic keratitis induced by herpes simplex virus type 1 (HSV-1) ocular infection is a leading infectious cause of blindness.
  • Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With T Cell Intracorneal Infiltration.

EyePoint Pharmaceuticals, Inc. - U.S. Commercialization of DEXYCU® (dexamethasone intraocular suspension) 9%

Retrieved on: 
Monday, July 8, 2019
Medical specialties, Medicine, Ophthalmology, Eye, Keratitis, Corneal ulcer, Herpes simplex keratitis, Uveitis, Corticosteroid, Sclera, Red eye, Corneal ulcers in animals

Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision

Key Points: 
  • Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision
    In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids
    The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures
    Fungal infections of the cornea are particularly prone to coincidentally develop with long-term local steroid application and must be considered in any persistent corneal ulceration where a steroid has been used or is in use.
  • Fungal culture should be taken when appropriate
    Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.
  • In acute purulent conditions, steroids may mask infection or enhance existing infection
    The most commonly reported adverse reactions occurred in 5-15% of subjects and included increases in intraocular pressure, corneal edema and iritis
    Link to the full Prescribing Information:
    DEXYCU is a registered trademark and the EyePoint logo is a trademark of EyePoint Pharmaceuticals, Inc.
    Verisome is a registered trademark of Ramscor, Inc.

Fera Pharmaceuticals Announces FDA Approval of Avaclyr™ (acyclovir ophthalmic ointment)

Retrieved on: 
Monday, April 1, 2019
Seniors, Health, Hospitals, Infectious diseases, Optical, Pharmaceutical, FDA, Consumer, Family, Managed care, Medical specialties, RTT, Medicine, Health, Viral diseases, Ophthalmology, Sexually transmitted diseases and infections, Purines, Herpes simplex keratitis, Aciclovir, Herpes simplex, Food and Drug Administration

The US Food and Drug Administration (FDA) has approved Feras New Drug Application (NDA) for Avaclyr (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis.

Key Points: 
  • The US Food and Drug Administration (FDA) has approved Feras New Drug Application (NDA) for Avaclyr (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis.
  • Avaclyr approval is a major milestone for the company, noted Frank DellaFera, Feras founder and President.
  • Acyclovir is the gold standard treatment in herpes virus infections so it made sense to provide this therapy in an ophthalmic dosage form1.
  • Fera is thankful to FDA for approving Avaclyr, making it available to physicians and patients in the US.